Literature DB >> 33461150

Trust in a COVID-19 vaccine among people with substance use disorders.

Alexandra M Mellis1, Braeden C Kelly2, Marc N Potenza3, Jessica N Hulsey2.   

Abstract

Entities:  

Year:  2021        PMID: 33461150      PMCID: PMC7797771          DOI: 10.1016/j.drugalcdep.2021.108519

Source DB:  PubMed          Journal:  Drug Alcohol Depend        ISSN: 0376-8716            Impact factor:   4.492


× No keyword cloud information.
Dear Editor, Data suggest that individuals with substance use disorders (SUDs) are at elevated risk of COVID-19 (Wang et al., 2020). Following issues of scarcity and prioritization in access (Hert et al., 2021), addressing vaccine distribution and readiness is critical for reducing the burden of the pandemic on this population (Warren et al., 2020). Given that high-risk or episodic substance use is associated with decreased likelihood of receipt of other preventive vaccines (Lasser et al., 2011), addressing both systemic and individual factors is key to promoting vaccination. Here we highlight the need to consider individuals with SUDs concerning not only vaccine access, but also trust and readiness.

COVID-19 vaccine readiness

The Addiction Policy Forum conducted structured interviews with 87 US-based individuals (54 % female, mean age 43 years (SD = 12.8)) impacted by SUDs (18 % currently using substances, 14 % in treatment, 76 % in recovery, non-exclusive self-report) between September 10 and 27, 2020 with IntegReview IRB approval. Participants were recruited via the Addiction Policy Forum’s US network of patients, families, and survivors of SUDs. One-on-one interviews were conducted by 3 trained Addiction Policy Forum staff via telephone and video conferencing. When prompted about willingness to take a COVID-19 vaccine, responses encompassed immediate readiness (45 %), readiness after a delay (8 %), uncertainty (23 %), and unwillingness (25 %). Those who were hesitant cited a “rushed” process for development, possibilities of adverse effects, interactions with pre-existing conditions, and/or skepticism that they were at high risk for COVID-19 itself, with the following specific comments: “No. I would rather catch it, I don’t trust the government, I dunno, it’s so new I don’t want to be on the receiving end of it, I’m not high risk or anything. If I did catch it, I don’t foresee it being fatal for me. I don’t get flu vaccines.” – in recovery “Yes, if my personal doctor recommends it.” – receiving treatment “Absolutely, once it's been vetted.” – currently using

Trust and readiness

The APF prompted participants on sources of information in which they trusted when making health decisions. Most reported they trusted their doctor in making their healthcare decisions, even among those who were hesitant towards a vaccine. Family was cited next most frequently, with participants reporting overall reliance on multiple sources (physicians and health workers, social media, television/newspapers, radio, official website(s), NIH/CDC, family, research data/medical journals, internet). Few participants reported lack of trust in any sources. We also prompted individuals about their willingness to receive multi-dose vaccines. While this did not change overall willingness or trust for the majority of respondents, some cited barriers to vaccine uptake that would only increase with series vaccination and were exacerbated during COVID-19. These included difficulties scheduling appointments given work and childcare obligations, and restrictions in access to clinics due to COVID-19.

Conclusions

Distribution programs, especially for series vaccines, may encounter significant barriers from people with SUDs. Interventions that have been developed to promote vaccination uptake among people with mental illness, including both educational components and distribution programs, warrant consideration among people with SUDs (Miles et al., 2020). These perspectives highlight that physician-patient relationships are important to ensuring people with SUDs trust in COVID-19 vaccines as they are distributed.

Funding

Supported in part by the National Institute on Drug Abuse (NIDA), National Institutes of Health (NIH), U.S. Department of Health and Human Services (HHS).

Contributors statement

BK and JH contributed to project administration, data curation, and data collection. BK, JH, and AM contributed to data curation and coding of interviews. JH contributed funding. MP and JH contributed supervision and conceptualization. AM prepared the first draft. All authors discussed the results and contributed review and editing.

Declaration of Competing Interest

The authors declare that they have no conflict of interest with respect to the content of this manuscript. The authors alone are responsible for the content and writing of the manuscript. Dr. Potenza has the following disclosures. He has consulted for and advised Opiant Pharmaceuticals, Idorsia Pharmaceuticals, AXA, Game Day Data, and the Addiction Policy Forum; has received research support from the Mohegan Sun Casino, the Connecticut Council on Problem Gambling, and the National Center for Responsible Gaming; has participated in surveys, mailings or telephone consultations related to drug addiction, impulse control disorders or other health topics; and has consulted for law offices and gambling entities on issues related to impulse control or addictive disorders. The Addiction Policy Forum is a 501 (c) (3) organization based in North Bethesda, MD. The Addiction Policy Forum was founded in 2015 to help, through science and advocacy, patients and families impacted by addiction.
  12 in total

1.  Attitudes toward COVID-19 vaccination and willingness to pay: comparison of people with and without mental disorders in China.

Authors:  Fengyi Hao; Bokun Wang; Wanqiu Tan; Syeda Fabeha Husain; Roger S McIntyre; Xiangdong Tang; Ling Zhang; Xiaofan Han; Li Jiang; Nicholas W S Chew; Benjamin Yong-Qiang Tan; Bach Tran; Zhisong Zhang; Gia Linh Vu; Giang Thu Vu; Roger Ho; Cyrus S Ho; Vijay K Sharma
Journal:  BJPsych Open       Date:  2021-08-11

2.  COVID-19 vaccine willingness and cannabis use histories.

Authors:  Philip A Spechler; Jennifer L Stewart; Rayus Kuplicki; Martin P Paulus
Journal:  medRxiv       Date:  2021-04-28

3.  COVID-19 vaccine acceptability among people in Australia who inject drugs: Implications for vaccine rollout.

Authors:  Paul M Dietze; Cristal Hall; Olivia Price; Ashleigh C Stewart; Sione Crawford; Amy Peacock; Lisa Maher
Journal:  Drug Alcohol Rev       Date:  2021-11-09

4.  Correlates of Coronavirus Disease 2019 (COVID-19) Vaccine Hesitancy Among People Who Inject Drugs in the San Diego-Tijuana Border Region.

Authors:  Steffanie A Strathdee; Daniela Abramovitz; Alicia Harvey-Vera; Carlos F Vera; Gudelia Rangel; Irina Artamonova; Thomas L Patterson; Rylie A Mitchell; Angela R Bazzi
Journal:  Clin Infect Dis       Date:  2022-08-24       Impact factor: 20.999

5.  Media attention and Vaccine Hesitancy: Examining the mediating effects of Fear of COVID-19 and the moderating role of Trust in leadership.

Authors:  Lulin Zhou; Sabina Ampon-Wireko; Xinglong Xu; Prince Edwudzie Quansah; Ebenezer Larnyo
Journal:  PLoS One       Date:  2022-02-18       Impact factor: 3.240

6.  How Vaccine Ambivalence Can Lead People Who Inject Drugs to Decline COVID-19 Vaccination and Ways This Can Be Addressed: Qualitative Study.

Authors:  Ian David Aronson; Alex S Bennett; Mary-Andrée Ardouin-Guerrier; German Rivera-Castellar; Brent Gibson; Samantha Santoscoy; Brittney Vargas-Estrella
Journal:  JMIR Form Res       Date:  2022-03-23

Review 7.  COVID-19 and substance use disorders: a review of international guidelines for frontline healthcare workers of addiction services.

Authors:  Edoardo G Ostinelli; Katharine Smith; Caroline Zangani; Michael J Ostacher; Anne R Lingford-Hughes; James S W Hong; Orla Macdonald; Andrea Cipriani
Journal:  BMC Psychiatry       Date:  2022-03-31       Impact factor: 3.630

8.  Depression, anxiety and stress among people infected with COVID-19 in Dhaka and Chittagong cities.

Authors:  Mohammad Salim Zahangir; Md Rokonuzzaman
Journal:  Heliyon       Date:  2022-08-29

9.  Protecting patients and staff in residential treatment centers during exposure to COVID-19: commentary.

Authors:  Kimberly A Johnson; Carolyn Keough; Holly Hills; Wouter Vermeer; Rebecca Lengnick-Hall; Moira McNulty; Mark McGovern; Hendricks Brown
Journal:  Addict Sci Clin Pract       Date:  2021-07-30

10.  COVID-19 vaccine trust among clients in a sample of California residential substance use treatment programs.

Authors:  Carmen L Masson; Caravella McCuistian; Elana Straus; Sania Elahi; Maggie Chen; Valerie A Gruber; Thao Le; Joseph Guydish
Journal:  Drug Alcohol Depend       Date:  2021-06-18       Impact factor: 4.492

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.